Cargando…

The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis

c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Sa, Li, Jiuke, Hao, Ke, Yan, Jianping, Zhou, Hongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081544/
https://www.ncbi.nlm.nih.gov/pubmed/27786238
http://dx.doi.org/10.1038/srep35770
_version_ 1782462917604540416
author Ye, Sa
Li, Jiuke
Hao, Ke
Yan, Jianping
Zhou, Hongbin
author_facet Ye, Sa
Li, Jiuke
Hao, Ke
Yan, Jianping
Zhou, Hongbin
author_sort Ye, Sa
collection PubMed
description c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of these drugs from 9 studies including 1611 patients in target drug groups and 1605 patients in control groups. As a result, patients in target drugs group had longer progression free survival (PFS) (HR 0.80, 95% CI 0.66–0.99, p = 0.04) but not overall survival (OS) than those in control group, especially in Asian (HR 0.57, 95% CI 0.42–0.76, p < 0.001), Non-squamous (HR 0.79, 95% CI 0.64–0.97, p = 0.03), Phase III (HR 0.66, 95% CI 0.50–0.86, p = 0.002), previous treated (HR 0.77, 95% CI 0.63–0.95, p = 0.01) and small molecular compounds subgroups (HR 0.62, 95% CI 0.50–0.78, p < 0.001). In addition, target drugs did not affect the objective response rate (ORR) but improved disease control rate (DCR) (RR 1.22, 95% CI 1.02–1.46, p = 0.03) of NSCLC patients. Our study first indicated that targeting c-MET therapies improved PFS and DCR in advanced or metastatic NSCLC patients, especially in previous treated Asian patients with adenocarcinoma.
format Online
Article
Text
id pubmed-5081544
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50815442016-10-31 The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis Ye, Sa Li, Jiuke Hao, Ke Yan, Jianping Zhou, Hongbin Sci Rep Article c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of these drugs from 9 studies including 1611 patients in target drug groups and 1605 patients in control groups. As a result, patients in target drugs group had longer progression free survival (PFS) (HR 0.80, 95% CI 0.66–0.99, p = 0.04) but not overall survival (OS) than those in control group, especially in Asian (HR 0.57, 95% CI 0.42–0.76, p < 0.001), Non-squamous (HR 0.79, 95% CI 0.64–0.97, p = 0.03), Phase III (HR 0.66, 95% CI 0.50–0.86, p = 0.002), previous treated (HR 0.77, 95% CI 0.63–0.95, p = 0.01) and small molecular compounds subgroups (HR 0.62, 95% CI 0.50–0.78, p < 0.001). In addition, target drugs did not affect the objective response rate (ORR) but improved disease control rate (DCR) (RR 1.22, 95% CI 1.02–1.46, p = 0.03) of NSCLC patients. Our study first indicated that targeting c-MET therapies improved PFS and DCR in advanced or metastatic NSCLC patients, especially in previous treated Asian patients with adenocarcinoma. Nature Publishing Group 2016-10-27 /pmc/articles/PMC5081544/ /pubmed/27786238 http://dx.doi.org/10.1038/srep35770 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Ye, Sa
Li, Jiuke
Hao, Ke
Yan, Jianping
Zhou, Hongbin
The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
title The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
title_full The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
title_fullStr The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
title_full_unstemmed The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
title_short The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
title_sort efficacy and risk profile of c-met inhibitors in non-small cell lung cancer: a meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081544/
https://www.ncbi.nlm.nih.gov/pubmed/27786238
http://dx.doi.org/10.1038/srep35770
work_keys_str_mv AT yesa theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT lijiuke theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT haoke theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT yanjianping theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT zhouhongbin theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT yesa efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT lijiuke efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT haoke efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT yanjianping efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis
AT zhouhongbin efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis